Antivirals from the Cloudbreak platform couple a potent antiviral targeting domain to a human antibody fragment. The antiviral conjugates directly inhibit viral proliferation while simultaneously engaging the immune system, according to Cidara.

The agreement will help Cidara move its CD388 conjugate through phase II development, it said. Janssen will be responsible for late-stage development, manufacturing, registration, and commercialization. Cidara will receive upfront payment of $27 million and will be eligible to receive up to $753 million in research and development funding, milestone recognition, and royalties on global sales.

Cidara plans to file an investigational new drug application for CD388 with the U.S. Food and Drug Administration by the end of the year.

Janssen COVID-19 vaccine authorized in EU
Just hours after receiving a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use on March 11,...

Janssen COVID-19 vaccine issued WHO authorization
Johnson & Johnson has been issued an emergency use listing by the World Health Organization (WHO) for the Janssen single-shot COVID-19 vaccine to...

Janssen COVID-19 vaccine nearing European approval
Johnson & Johnson announced it has moved a step closer toward marketing authorization for its single-dose COVID-19 vaccine candidate in Europe.

Janssen COVID-19 vaccine becomes 3rd authorized in U.S.
Janssen Biotech's COVID-19 vaccine has received an emergency use authorization from the U.S. Food and Drug Administration. The move allows the vaccine...

J&J submits Janssen COVID-19 vaccine to WHO for emergency use listing
Johnson & Johnson announced it has submitted Janssen's investigational single-dose COVID-19 vaccine candidate to the World Health Organization (WHO)...